Associate Director, in vivo Toxicology
CRISPR Therapeutics is hiring for Associate Director, in vivo Toxicology in South Boston, MA. Manager level, $160k–$180k a year stated. First seen November 6, 2026; open as of November 13, 2026. Jobs taken straight from company career pages — no aggregator in between.
With Destava: How well do you fit? · Tailor my résumé · Write a cover letter
- Company
- CRISPR Therapeutics
- Where
- South Boston, MA
- Level
- Manager
- Pay stated
- $160k–$180k a year
- First seen
- November 6, 2026
- Listed via
- Workday
What the posting says
Position Summary CRISPR Therapeutics seeks an experienced toxicologist to advance IND-enabling pharmacology studies for our in vivo programs. Reporting to the Director, Head of in vivo Toxicology the position will work cross functionally as a toxicology, pharmacology, and DMPK subject matter expert to drive our in vivo nonclinical strategy forward. Responsibilities - Designs, prepares protocols for, ensures appropriate resourcing for, monitors, and reviews reports for non-clinical non-GLP and GLP studies performed internally and at external vendors to support product development. - Supports…
Read more and apply on CRISPR Therapeutics' site
More jobs like this
Vice President, Head of Translational Science and Medicine
Save to applySenior Scientist, Discovery Science
Save to applyScientist, Cellular Immunology and Inflammation
Save to applyResearch Fellow in Atherosclerosis Inflammation at MGH Cardiovascular Research Center’s Jaffer Lab
Save to apply
See all 155 Medical Scientists, Except Epidemiologists jobs in Boston
A search agent finds the jobs this list misses: the ones that mean the same without the same words. Have Destava watch for associate director, in vivo toxicology jobs in South Boston, MA, new matches every morning on your own account.
This page includes information from the O*NET 31.0 Database by the U.S. Department of Labor, Employment and Training Administration (USDOL/ETA). Used under the CC BY 4.0 license. O*NET® is a trademark of USDOL/ETA.